Titan Medical's New Chapter with Conavi Medical
Titan Medical Inc. (TSX: TMD; OTC: TMDIF) is thrilled to share its management information circular, marking an important milestone in its planned merger with Conavi Medical Inc. This strategic decision is not just a merger; it represents a transformative opportunity for Titan's shareholders.
Overview of the Amalgamation Agreement
The recently unveiled amalgamation agreement lays the groundwork for an all-stock transaction between Titan Medical and Conavi Medical. This process signifies a reverse takeover of Titan, aimed at uniting the innovative capabilities of both companies under one umbrella.
Implications for Shareholders
Paul Cataford, Titan’s Interim CEO, highlights the potential of this merger, stating, "The Circular presents a compelling case for our shareholders to support this reverse merger with Conavi. We are confident that this transaction provides our existing shareholders with a unique opportunity to be part of a groundbreaking commercial-stage venture. Our financial advisors have confirmed the fairness of this deal, and we strongly encourage shareholders to vote in favor of this transaction."
Key Details of the Upcoming Transaction
This transaction is set to bring a host of benefits for Titan and its shareholders:
- Increased investment potential in a growing market.
- Shareholders will maintain a substantial stake in the newly formed entity.
- A robust leadership team will steer the merged company, driving growth in advanced medical devices.
- The closing conditions include a minimum of $7.5 million in equity financing, which will provide essential capital for the merged operation.
Scheduled Meeting for Shareholder Approval
Titan will hold its annual general and special meeting on September 30, 2024. During this virtual gathering, shareholders will have the opportunity to vote on the transaction. Cataford encourages shareholders to carefully review the Circular and to cast their votes before the deadline, ensuring they play a role in this crucial moment for Titan Medical.
Engagement with Shareholders
Titan is dedicated to keeping its shareholders informed throughout this process. To facilitate discussions and address any questions, a Q&A session will be organized prior to the meeting. Shareholders are invited to send their inquiries about this transaction to Titan's dedicated email address, ensuring every voice is heard.
Unanimous Support from the Board
The board of Titan has fully backed the agreement, unanimously supporting the merger. They have received an opinion from Raymond James, confirming that the terms of the transaction are fair from a financial perspective. This endorsement reflects the board's confidence in the company’s future direction.
About Titan Medical
Titan Medical Inc. is a leading medical technology company focused on enhancing robotic-assisted surgery. Based in Toronto, Ontario, Titan holds an impressive portfolio of patents and is actively exploring opportunities to further develop its intellectual property while increasing shareholder value.
About Conavi Medical
Conavi Medical Inc. specializes in cutting-edge imaging technologies that are critical for minimally invasive cardiovascular procedures. Their patented Novasight Hybrid™ System represents a significant advancement in the field, having received important regulatory approvals and positioning them strongly in the medical technology sector.
Frequently Asked Questions
What is the rationale behind the merger with Conavi Medical?
Titan believes this transaction will create growth opportunities and combine the innovative technologies from both companies, ultimately generating value for shareholders.
When will the shareholder meeting take place?
The meeting is set for September 30, 2024, at 4:00 p.m. Eastern Time.
How can shareholders participate in the voting process?
Shareholders can vote during the virtual meeting or in advance before the voting deadline on September 26, 2024.
What assistance is available for shareholders with questions regarding the merger?
Shareholders can contact Shorecrest Group via telephone or email for any help or inquiries they may have.
What is Titan's strategic focus moving forward?
Titan aims to further develop and license its technologies, expand its market presence, and enhance shareholder value through innovative partnerships and financial growth.
